vs
Side-by-side financial comparison of LivaNova PLC (LIVN) and Westrock Coffee Co (WEST). Click either name above to swap in a different company.
LivaNova PLC is the larger business by last-quarter revenue ($360.9M vs $339.5M, roughly 1.1× Westrock Coffee Co). LivaNova PLC runs the higher net margin — 8.6% vs -6.6%, a 15.2% gap on every dollar of revenue. On growth, Westrock Coffee Co posted the faster year-over-year revenue change (48.3% vs 12.1%). LivaNova PLC produced more free cash flow last quarter ($50.2M vs $27.8M). Over the past eight quarters, Westrock Coffee Co's revenue compounded faster (32.8% CAGR vs 10.6%).
LivaNova, plc is an American medical device manufacturer based in the UK. The company develops devices used for cardiac surgery and neuromodulation. The company was formed in 2015 by a $2.7B merger between Houston, Texas-based Cyberonics, Inc. and Milan, Italy-based Sorin S.p.a. The company trades on the NASDAQ stock exchange under the ticker symbol "LIVN".
Westrock Coffee Co is a global integrated coffee, tea and functional beverage solutions provider. It sources, roasts, manufactures and distributes coffee products, ready-to-drink beverages and custom formulations for retail, foodservice and commercial clients across North America and other key markets.
LIVN vs WEST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $360.9M | $339.5M |
| Net Profit | $30.9M | $-22.6M |
| Gross Margin | 65.2% | 11.5% |
| Operating Margin | 11.8% | -2.6% |
| Net Margin | 8.6% | -6.6% |
| Revenue YoY | 12.1% | 48.3% |
| Net Profit YoY | -44.7% | 8.3% |
| EPS (diluted) | $0.57 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $360.9M | $339.5M | ||
| Q3 25 | $357.8M | $354.8M | ||
| Q2 25 | $352.5M | $280.9M | ||
| Q1 25 | $316.9M | $213.8M | ||
| Q4 24 | $321.8M | $229.0M | ||
| Q3 24 | $318.1M | $220.9M | ||
| Q2 24 | $318.6M | $208.4M | ||
| Q1 24 | $294.9M | $192.5M |
| Q4 25 | $30.9M | $-22.6M | ||
| Q3 25 | $26.8M | $-19.1M | ||
| Q2 25 | $27.2M | $-21.6M | ||
| Q1 25 | $-327.3M | $-27.2M | ||
| Q4 24 | $55.9M | $-24.6M | ||
| Q3 24 | $33.0M | $-14.3M | ||
| Q2 24 | $16.3M | $-17.8M | ||
| Q1 24 | $-41.9M | $-23.7M |
| Q4 25 | 65.2% | 11.5% | ||
| Q3 25 | 68.4% | 11.7% | ||
| Q2 25 | 67.8% | 14.7% | ||
| Q1 25 | 69.7% | 13.6% | ||
| Q4 24 | 68.2% | 16.6% | ||
| Q3 24 | 70.8% | 16.8% | ||
| Q2 24 | 68.7% | 19.9% | ||
| Q1 24 | 70.3% | 19.4% |
| Q4 25 | 11.8% | -2.6% | ||
| Q3 25 | 15.1% | -2.4% | ||
| Q2 25 | 15.4% | -5.3% | ||
| Q1 25 | 15.3% | -6.1% | ||
| Q4 24 | 11.5% | -4.3% | ||
| Q3 24 | 11.2% | -5.8% | ||
| Q2 24 | 12.6% | -7.9% | ||
| Q1 24 | 5.5% | -5.3% |
| Q4 25 | 8.6% | -6.6% | ||
| Q3 25 | 7.5% | -5.4% | ||
| Q2 25 | 7.7% | -7.7% | ||
| Q1 25 | -103.3% | -12.7% | ||
| Q4 24 | 17.4% | -10.7% | ||
| Q3 24 | 10.4% | -6.5% | ||
| Q2 24 | 5.1% | -8.5% | ||
| Q1 24 | -14.2% | -12.3% |
| Q4 25 | $0.57 | $-0.22 | ||
| Q3 25 | $0.49 | $-0.20 | ||
| Q2 25 | $0.50 | $-0.23 | ||
| Q1 25 | $-6.01 | $-0.29 | ||
| Q4 24 | $1.04 | $-0.26 | ||
| Q3 24 | $0.60 | $-0.16 | ||
| Q2 24 | $0.30 | $-0.20 | ||
| Q1 24 | $-0.78 | $-0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $635.6M | $49.9M |
| Total DebtLower is stronger | $376.1M | $444.1M |
| Stockholders' EquityBook value | $1.2B | $-1.9M |
| Total Assets | $2.6B | $1.2B |
| Debt / EquityLower = less leverage | 0.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $635.6M | $49.9M | ||
| Q3 25 | $646.1M | $34.0M | ||
| Q2 25 | $593.6M | $44.0M | ||
| Q1 25 | $738.4M | $33.1M | ||
| Q4 24 | $428.9M | $26.2M | ||
| Q3 24 | $346.4M | $22.4M | ||
| Q2 24 | $329.2M | $24.3M | ||
| Q1 24 | $309.2M | $12.6M |
| Q4 25 | $376.1M | $444.1M | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | $393.1M | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $-1.9M | ||
| Q3 25 | $1.2B | $11.4M | ||
| Q2 25 | $1.1B | $18.2M | ||
| Q1 25 | $1.0B | $71.4M | ||
| Q4 24 | $1.3B | $97.5M | ||
| Q3 24 | $1.3B | $110.3M | ||
| Q2 24 | $1.2B | $81.5M | ||
| Q1 24 | $1.2B | $91.7M |
| Q4 25 | $2.6B | $1.2B | ||
| Q3 25 | $2.6B | $1.2B | ||
| Q2 25 | $2.5B | $1.2B | ||
| Q1 25 | $2.6B | $1.1B | ||
| Q4 24 | $2.5B | $1.1B | ||
| Q3 24 | $2.5B | $1.1B | ||
| Q2 24 | $2.5B | $1.1B | ||
| Q1 24 | $2.5B | $983.3M |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | 4.03× | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.4M | $36.7M |
| Free Cash FlowOCF − Capex | $50.2M | $27.8M |
| FCF MarginFCF / Revenue | 13.9% | 8.2% |
| Capex IntensityCapex / Revenue | 8.9% | 2.6% |
| Cash ConversionOCF / Net Profit | 2.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | $173.3M | $-107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.4M | $36.7M | ||
| Q3 25 | $85.1M | $-26.6M | ||
| Q2 25 | $62.9M | $-7.0M | ||
| Q1 25 | $24.0M | $-22.1M | ||
| Q4 24 | $78.7M | $2.8M | ||
| Q3 24 | $51.0M | $-332.0K | ||
| Q2 24 | $43.4M | $-23.7M | ||
| Q1 24 | $10.0M | $8.0M |
| Q4 25 | $50.2M | $27.8M | ||
| Q3 25 | $62.2M | $-44.7M | ||
| Q2 25 | $47.8M | $-27.5M | ||
| Q1 25 | $13.2M | $-63.4M | ||
| Q4 24 | $68.3M | $-15.4M | ||
| Q3 24 | $32.8M | $-36.7M | ||
| Q2 24 | $31.2M | $-59.9M | ||
| Q1 24 | $3.6M | $-60.9M |
| Q4 25 | 13.9% | 8.2% | ||
| Q3 25 | 17.4% | -12.6% | ||
| Q2 25 | 13.6% | -9.8% | ||
| Q1 25 | 4.2% | -29.7% | ||
| Q4 24 | 21.2% | -6.7% | ||
| Q3 24 | 10.3% | -16.6% | ||
| Q2 24 | 9.8% | -28.7% | ||
| Q1 24 | 1.2% | -31.7% |
| Q4 25 | 8.9% | 2.6% | ||
| Q3 25 | 6.4% | 5.1% | ||
| Q2 25 | 4.3% | 7.3% | ||
| Q1 25 | 3.4% | 19.3% | ||
| Q4 24 | 3.2% | 7.9% | ||
| Q3 24 | 5.7% | 16.5% | ||
| Q2 24 | 3.8% | 17.4% | ||
| Q1 24 | 2.2% | 35.8% |
| Q4 25 | 2.67× | — | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 2.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.41× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 2.65× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
WEST
| Coffee And Tea | $202.6M | 60% |
| Flavors Extracts And Ingredients | $69.6M | 21% |
| Sustainable Sourcing And Traceability Segments | $66.9M | 20% |
